LTRN
Lantern Pharma Inc. Common Stock
$3.230+-0.000 (-0.000%)
即時價格
價格圖表
Loading Chart...
關鍵指標
市場指標
開盤
$3.230
最高
$3.230
最低
$3.230
交易量
0.11M
公司基本面
交易統計
相關新聞
BusinessWire
Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates
Completion of LP-184 Phase 1a clinical trial enrollment with 62-65 patients across a range of solid tumors expected by end of June 2025. Additional patient data readout from the HARMONIC™ Trial evaluating
查看更多
BusinessWire
Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC)
The FDA has cleared the investigational new drug (IND) application of LP-184 in triple negative breast cancer (TNBC) treatment – a novel small molecule advanced and developed with Lantern's AI platform,
查看更多
相關股票
保持更新
設定價格提醒，獲取AI分析更新和即時市場新聞。